Get the latest tech news
Low-cost B-cell depleting therapy is as effective as standard treatment for multiple sclerosis
A Norwegian Swedish clinical trial published in the New England Journal of Medicine (NEJM) demonstrates that rituximab, a low-cost B-cell depleting therapy, is as effective as ocrelizumab in newly diagnosed relapsing multiple sclerosis (MS).
None
Or read this on r/technology